Monte Rosa Therapeutics, Inc. (GLUE)

NASDAQ:
GLUE
| Latest update: Apr 15, 2026, 5:46 PM

Stock events for Monte Rosa Therapeutics, Inc. (GLUE)

In January 2026, GLUE stock reached a 52-week high and raised approximately $345 million gross through a follow-on equity offering. In March 2026, the company reported its Q4 and full-year 2025 financial results, which missed consensus estimates, but highlighted positive pipeline milestones. In April 2026, the Chief Business & Legal Officer sold 5,845 shares of common stock.

Demand Seasonality affecting Monte Rosa Therapeutics, Inc.’s stock price

Monte Rosa Therapeutics, as a clinical-stage biotechnology company, does not experience typical demand seasonality. Demand for its product candidates is driven by clinical trial progression, regulatory approvals, and medical need, rather than seasonal consumer purchasing patterns.

Overview of Monte Rosa Therapeutics, Inc.’s business

Monte Rosa Therapeutics, Inc. (GLUE) is a clinical-stage biotechnology company focused on developing innovative small molecule precision medicines using molecular glue degraders (MGDs). Their pipeline includes MRT-2359 for MYC-driven tumors, MRT-6160 for autoimmune and inflammatory diseases (partnered with Novartis), MRT-8102 for inflammatory diseases, and CDK2/Cyclin E1-directed MGDs for various cancers. The company utilizes its QuEEN discovery engine and has collaborations with Roche and Novartis.

GLUE’s Geographic footprint

Monte Rosa Therapeutics, Inc. is headquartered in Boston, Massachusetts, United States, and operates within the United States market.

GLUE Corporate Image Assessment

Monte Rosa Therapeutics' brand reputation has been positively influenced by positive interim Phase 1 data for MRT-8102, the 100% PSA response rate observed with MRT-2359, strategic collaborations with Novartis and Roche, and its QuEEN discovery engine. Events affecting reputation include a significant miss on Q4 2025 revenue, shareholder dilution, and insider selling activity. The company has a "Moderate Buy" consensus rating from analysts.

Ownership

Monte Rosa Therapeutics has substantial institutional ownership, with 165 institutional owners holding approximately 79.96% of the stock. Major institutional owners include NEA Management Company, LLC, Price T Rowe Associates Inc, TCG Crossover Management, LLC, Versant Venture Management, LLC, Baker Bros. Advisors Lp, BlackRock, Inc., Bvf Inc/il, Suvretta Capital Management, Llc, Vanguard Group Inc, State Street Corp, New Enterprise Associates, Inc., and Dimension Capital I, L.P. Individual insiders hold approximately 0.593% of the shares and have sold more shares than they have bought in the past three months.

Price Chart

$18.32

4.69%
(1 month)

Top Shareholders

NEA Management Co. LLC
12.46%
T. Rowe Price Group, Inc.
8.29%
TCG Crossover Management LLC
7.48%
Versant Venture Management LLC
7.10%
Baker Bros. Advisors LP
7.04%
BlackRock, Inc.
6.77%
BVF, Inc.
6.21%
Suvretta Capital LP
5.44%

Trade Ideas for GLUE

Today

Sentiment for GLUE

News
Social

Buzz Talk for GLUE

Today

Social Media

FAQ

What is the current stock price of Monte Rosa Therapeutics, Inc.?

As of the latest update, Monte Rosa Therapeutics, Inc.'s stock is trading at $18.32 per share.

What’s happening with Monte Rosa Therapeutics, Inc. stock today?

Today, Monte Rosa Therapeutics, Inc. stock is up by 4.69%, possibly due to news.

What is the market sentiment around Monte Rosa Therapeutics, Inc. stock?

Current sentiment around Monte Rosa Therapeutics, Inc. stock is negative, based on recent news, trading volume, and analyst opinions.

Is Monte Rosa Therapeutics, Inc.'s stock price growing?

Over the past month, Monte Rosa Therapeutics, Inc.'s stock price has increased by 4.69%.

How can I buy Monte Rosa Therapeutics, Inc. stock?

You can buy Monte Rosa Therapeutics, Inc. stock through any brokerage platform, such as e.g., Robinhood, Fidelity, E*TRADE, by searching for the ticker symbol GLUE

Who are the major shareholders of Monte Rosa Therapeutics, Inc. stock?

Major shareholders of Monte Rosa Therapeutics, Inc. include institutions such as NEA Management Co. LLC (12.46%), T. Rowe Price Group, Inc. (8.29%), TCG Crossover Management LLC (7.48%) ... , according to the latest filings.